Showing 1401-1410 of 1477 results for "".
- Biomarker Indicating Neurodegeneration Identified in the Eyehttps://modernod.com/news/biomarker-indicating-neurodegeneration-identified-in-the-eye/2478302/A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye. Neurofilament light chain, a protein previously detected in cerebrospinal fluid and blood that is
- AMA Issues CPT Category III Codes for Artificial Iris Implantationhttps://modernod.com/news/ama-issues-cpt-category-iii-codes-for-artificial-iris-implantation/2478255/VEO Ophthalmics announced that the American Medical Association (AMA) has issued three CPT codes for the “Insertion of Iris Prosthesis.” The CPT Category III codes are: 0616T, 0617T, and 0618T and are effective July 1, 2020. Earlier this year, the
- Hospital Operating Margins Down 28% Through July: Reporthttps://modernod.com/news/hospital-operating-margins-down-28-through-july-report/2478199/While there have been some early signs of recovery, uncertainty and volatility caused by the COVID-19 pandemic continued to rock hospital financials through the end of July, a new report says, according to a FierceHealthcare
- How COVID-19 Causes Smell Losshttps://modernod.com/news/how-covid-19-causes-smell-loss/2478103/Temporary loss of smell, or anosmia, is the main neurological symptom and one of the earliest and most commonly reported indicators of COVID-19. Studies suggest it better predicts the disease than other well-known symptoms such as fever and cough, but the underlying mechan
- J&J Vaccine Protects Monkeys From Covid With Single Shothttps://modernod.com/news/jj-vaccine-protects-monkeys-from-covid-with-single-shot/2478099/Johnson & Johnson’s experimental coronavirus vaccine protected a group of macaques with a single shot in an early study, prompting the U.S. drugmaker to start trials in humans this month, according to a Bloomberg
- Glaucoma Study Findings Emphasize Need for Regular Eye Checkshttps://modernod.com/news/glaucoma-study-findings-emphasize-need-for-regular-eye-checks/2478048/People with early-stage glaucoma see the contrast of visible objects in a very similar way to people without the condition, a new study has shown. Research by the University of Bradford (UK) demonstrated that the brain compensates for the changes in the eye caused by glaucoma, when looking
- Oxford-AstraZeneca Covid Vaccine Study Shows Dual Immune Actionhttps://modernod.com/news/oxford-astrazeneca-covid-vaccine-study-shows-dual-immune-action/2478042/A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen, according to a Bloomberg
- Novavax Gains $1.6 Billion in Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-gains-1-6-billion-in-funding-for-covid-19-vaccine-candidate/2477984/Novavax announced that it has been awarded $1.6 billion by the US government to progress development of NVX CoV2373 and potentially deliver 100 million doses of the COVID-19 vaccine as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using Novavax’s nanop
- Sanofi Sees Potential Approval of COVID-19 Vaccine in First Half of 2021https://modernod.com/news/sanofi-sees-potential-approval-of-covid-19-vaccine-in-first-half-of-2021/2477923/Sanofi said Tuesday that it expects potential approval of a COVID-19 vaccine being jointly developed with GlaxoSmithKline in the first half of next year, brought forward from an earlier estimate of the second half of 2021. A phase 1/2 study of the recombinant protein-based vaccine approach, whic
- Gilead Looking to Test Easier-To-Use, Inhaled Version of Remdesivirhttps://modernod.com/news/gilead-to-begin-human-trials-for-the-inhaled-version-of-coronavirus-drug-remdesivir/2477919/Gilead Sciences said Monday that it hopes to begin clinical trials this summer evaluating an inhaled formulation of remdesivir, administered via a nebuliser, to patients with COVID-19. The experimental antiviral, which the FDA authorized for emergency use in early May, is currently given intraven